The burden of neurological comorbidities in six autoimmune bullous diseases: a population-based study.

Szczegóły
Abstrakt

Tytuł:: The burden of neurological comorbidities in six autoimmune bullous diseases: a population-based study.
Autorzy:: Kridin K; Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.; Unit of Dermatology and Skin Research Laboratory, Baruch Padeh Poria Medical Center, Tiberias, Israel.
Hübner F; Department of Dermatology, University of Lübeck, Lübeck, Germany.
Recke A; Department of Dermatology, University of Lübeck, Lübeck, Germany.
Linder R; Techniker Krankenkasse, Corporate Development, Analytics and Insights, Hamburg, Germany.
Schmidt E; Lűbeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.; Department of Dermatology, University of Lübeck, Lübeck, Germany.
Źródło:: Journal of the European Academy of Dermatology and Venereology : JEADV [J Eur Acad Dermatol Venereol] 2021 Oct; Vol. 35 (10), pp. 2074-2078. Date of Electronic Publication: 2021 Aug 04.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: Oxford : Wiley-Blackwell
Original Publication: Amsterdam ; New York : Elsevier Science Publishers, c1992-
MeSH Terms:: Autoimmune Diseases*/complications
Autoimmune Diseases*/epidemiology
Epidermolysis Bullosa Acquisita*
Skin Diseases, Vesiculobullous*/epidemiology
Cross-Sectional Studies ; Humans ; Retrospective Studies
References:: Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet 2019; 394: 882-894.
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332.
van Beek N, Zillikens D, Schmidt E. Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges 2018; 16: 1077-1091.
Kridin K, Zelber-Sagi S, Bergman R. Mortality and cause of death in patients with pemphigus. Acta Derm Venereol 2017; 97: 607-611.
Kridin K, Schwartz N, Cohen AD, Zelber-Sagi S. Mortality in bullous pemphigoid: a systematic review and meta-analysis of standardized mortality ratios. J Dermatol 2018; 45: 1094-1100.
Ständer S, Färber B, Radeke S, Schmidt E, Zillikens D, Ludwig RJ. Assessment of healthcare costs for patients with pemphigus and bullous pemphigoid in an academic centre in Germany. BrJ Dermatol 2020; 182: 1296-1297.
Hsu D, Brieva J, Silverberg JI. Costs of care for hospitalization for pemphigus in the United States. JAMA Dermatol 2016; 152: 645-654.
Lai Y, Yew Y, Lambert W. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2016; 30: 2007-2015.
Taghipour K, Chi C-C, Vincent A, Groves RW, Venning V, Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study. Arch Dermatol 2010; 146: 1251-1254.
Daneshpazhooh M, Khorassani J, Balighi K et al. Neurological diseases and bullous pemphigoid: a case-control study in Iranian patients. Indian J Dermatol Venereol Leprol 2017; 83.
Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131: 631-636.
Gambichler T, Segert H, Hoxtermann S, Schmitz L, Altmeyer P, Teegen B. Neurological disorders in patients with bullous pemphigoid: clinical and experimental investigations. J Eur Acad Dermatol Venereol 2015; 29: 1758-1762.
Papakonstantinou E, Limberg MM, Gehring M et al. Neurological disorders are associated with bullous pemphigoid. J Eur Acad Dermatology Venereol 2019; 33: 925-929.
Försti AK, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid-more than skin deep? Exp Dermatol 2017; 26: 1228-1234.
Kridin K, Zelber-Sagi S, Comaneshter D, Cohen AD. Association between pemphigus and neurologic diseases. JAMA Dermatol 2018; 154: 281.
Wills AJ, Turner B, Lock RJ, Johnston SL, Unsworth DJ, Fry L. Dermatitis herpetiformis and neurological dysfunction. J Neurol Neurosurg Psychiatry 2002; 72: 259-261.
Müller BS, Uhlmann L, Ihle P et al. Development and internal validation of prognostic models to predict negative health outcomes in older patients with multimorbidity and polypharmacy in general practice. BMJ Open 2020; 10: e039747.
Kokkonen N, Herukka SK, Huilaja L et al. Increased levels of the bullous pemphigoid BP180 autoantibody are associated with more severe dementia in Alzheimer’s disease. J Invest Dermatol 2017; 137: 71-76.
Petrera MR, Tampoia M, Guida S, Abbracciavento L, Fumarulo R, Foti C. Bullous pemphigoid and neurologic diseases: toward a specific serologic profile? Endocr Metab Immune Disord Drug Targets 2018; 18: 662-664.
Meudec L, Amode R, Brunet-Possenti F, Mignot S, Descamps V. Presence of anti-BP180 and anti-BP230 in the cerebrospinal fluid of patients with bullous pemphigoid and neurological disease: is there any intrathecal synthesis? Br J Dermatol 2019; 181: 828-829.
Iwata H, Vorobyev A, Koga H et al. Meta-analysis of the clinical and immunopathological characteristics and treatment outcomes in epidermolysis bullosa acquisita patients. Orphanet J Rare Dis 2018; 13: 153. https://doi.org/10.1186/s13023-018-0896-1.
Paulus W, Baur I, Liszka U, Drlicek M, Leigh I, Bruckner-Tuderman L. Expression of type VII collagen, the major anchoring fibril component, in normal and neoplastic human nervous system. Virchows Arch 1995; 426: 199-202.
Vecino E, Kwok JCF. The extracellular matrix in the nervous system: the good and the bad aspects. In: Composition and Function of the Extracellular Matrix in the Human Body [Internet]. InTech; 2016. URL http://dx.doi.org/10.5772/62527 (last accessed: 8 May 2021).
Uhlén M, Fagerberg L, Hallström BM et al. Tissue-based map of the human proteome. Science 2015; 347: 1260419.
Miyata S, Yoshikawa K, Taniguchi M et al. Sgk1 regulates desmoglein 1 expression levels in oligodendrocytes in the mouse corpus callosum after chronic stress exposure. Biochem Biophys Res Commun 2015; 464: 76-82.
Kljuic A, Christiano AM. A novel mouse desmosomal cadherin family member, desmoglein 1 gamma. Exp Dermatol 2003; 12: 20-29.
Eming R, Sticherling M, Hofmann SC et al. S2k-Leitlinie zur therapie des pemphigus vulgaris/foliaceus und des bullösen pemphigoid. J Dtsch Dermatol Ges 2015; 13: 833-845.
Höfler M. The Bradford Hill considerations on causality: a counterfactual perspective. Emerg Themes Epidemiol 2005; 2: 11.
Grant Information:: KFO 303 Clinical Research Unit Pemphigoid Diseases; EXC 2167 Cluster of Excellence Precision Medicine in Chronic Inflammation; Deutsche Forschungsgemeinschaft
Entry Date(s):: Date Created: 20210621 Date Completed: 20210920 Latest Revision: 20210920
Update Code:: 20240105
DOI:: 10.1111/jdv.17465
PMID:: 34153122
: Czasopismo naukowe

Full Text Finder

Background: Apart from bullous pemphigoid (BP), the association of other autoimmune bullous diseases (AIBDs) with neurological conditions is poorly understood.
Objective: To estimate the association between a wide array of AIBDs and neurological conditions.
Methods: A retrospective cross-sectional study recruited patients with BP, mucous membrane pemphigoid (MMP), epidermolysis bullosa acquisita (EBA), pemphigoid gestationis (PG), pemphigus vulgaris (PV) and pemphigus foliaceus (PF). These patients were compared with their age- and sex-matched control subjects with regard to the lifetime prevalence of Parkinson's disease (PD), Alzheimer's disease (AD), stroke, epilepsy and multiple sclerosis (MS). Logistic regression was used to calculate OR for specified neurological disorders.
Results: The current study included 1743, 251, 106, 126, 860 and 103 patients diagnosed with BP, MMP, EBA, PG, PV and PF, respectively. These patients were compared with 10 141, 1386, 606, 933, 5142 and 588 matched controls, respectively. Out of the investigated neurological conditions, PD associated with BP (OR, 2.71; 95% CI, 2.19-3.35); AD with BP (OR, 2.11; 95% CI, 1.73-2.57), MMP (OR, 2.37; 95% CI, 1.03-5.47), EBA (OR, 6.00; 95% CI, 1.90-18.97) and PV (OR, 2.24; 95% CI, 1.40-3.60); stroke with BP (OR, 1.84; 95% CI, 1.55-2.19) and EBA (OR, 2.79; 95% CI, 1.11-7.01); and epilepsy with BP (OR, 2.18; 95% CI, 1.72-2.77) and PV (OR, 1.80; 95% CI, 1.19-2.73). MS did not significantly cluster with any of the six AIBDs.
Conclusion: In addition to BP, EBA and PV were found to cluster with neurological comorbidities. Patients with these AIBDs with compatible symptoms may be carefully assessed for comorbid neurological disorders.
(© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.)

Informacja